Analytical Data
-
基因名
CD40
- Application
-
别名
CD40；TNFRSF5；Tumor necrosis factor receptor superfamily member 5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P25942
-
表达区间
21-193aa
-
氨基酸序列
EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDT WNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCV LHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETK DLVVQQAGTNKTDVVCGPQDRLR
-
分子量
45 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD40 is a costimulatory protein found on antigen-presenting cells and plays a crucial role in the immune response by facilitating communication between these cells and T cells. Its interaction with CD40 ligand (CD40L) on T cells enhances the activation, proliferation, and survival of B cells, leading to antibody production and immune memory formation. Given its pivotal role in regulating humoral immunity, CD40 and its signaling pathways have become attractive targets for therapeutic interventions in various diseases, including cancers, autoimmune disorders, and infectious diseases. Research into recombinant CD40 proteins involves engineering these molecules for enhanced functionality, stability, and delivery. Such advancements could improve vaccine efficacy, boost immune responses in cancer therapies, and help in the development of monoclonal antibodies. Furthermore, understanding the structural and functional properties of CD40 can provide insights into its biological mechanisms and potentially reveal new avenues for manipulating immune responses for therapeutic benefit. The ongoing study of CD40 recombinant proteins not only promises to advance basic immunology but also holds significant potential for influencing future clinical applications in immunotherapy and vaccine development.
